Vector-Borne Disease Testing Panel
Borrelia, Babesia and Bartonella are stealth pathogens, low-abundance, slow-replicating organisms that suppress immune response and evade detection. Although lab-developed testing has improved, most diagnostics still rely on indirect markers, missing the root of the problem.
Every assay we use is optimized in-house and rigorously validated by our team of scientists to ensure clinical relevance, so providers get actionable results even when other tests fall short.
Nanotrap® technology captures and concentrates Borrelia antigens directly from urine, dramatically increasing sensitivity, especially in early-stage Lyme and complex chronic cases. Unlike antibody tests, it detects the pathogen itself, not the body’s immune response.
Galaxy's Digital PCR breaks samples into thousands of partitions, detecting trace amounts of pathogen DNA that other technologies miss. Originally pioneered in oncology, now adapted for infectious disease.
The most comprehensive Bartonella IgG IFA panel available, targeting the four species most associated with human disease, built using clinical isolates, not commercial slides and reported as titers.
Get the direct evidence needed to guide next steps, not just past exposure.
Helps you catch infections others miss, before they become harder to treat.
Vetted by published data, not just internal claims.
You shouldn’t need a specialist to interpret your results, though we’re here if you need us.
See which direct detection method fits your next case, urine antigen, digital PCR, or Bartonella serology.
Galaxy’s testing panel combines three technologies for direct detection of Borrelia, Babesia, and Bartonella: Nanotrap urine antigen testing, digital PCR (dPCR), and Bartonella IgG IFA serology. Each test targets a different type of pathogen presence, so the right combination depends on the clinical picture.
Standard antibody testing measures immune response, which can be delayed, variable, or suppressed. Direct detection methods, like Galaxy’s Nanotrap urine antigen test and digital PCR, look for the pathogen itself, DNA or antigen, which can identify cases that antibody testing misses.
Digital PCR breaks each blood sample into thousands of partitions and tests each one for pathogen DNA, a method originally developed in oncology. This partitioning increases the odds of detecting trace amounts of Bartonella, Babesia, or Borrelia DNA that other technologies can miss.
In a study of acute Lyme patients, Galaxy’s Nanotrap urine antigen test identified pathogen presence in cases that standard serology missed, with up to 2x greater sensitivity (Magni et al., 2015, J Transl Med).
In a high-risk patient population, digital PCR identified Bartonella DNA in blood at roughly 6 times the rate of standard PCR (Maggi et al., 2020, J Microbiol Methods).
Galaxy’s digital PCR testing uses a 3-day blood draw protocol, which increases the probability of capturing pathogens that circulate at low, intermittent levels in the bloodstream.
